-
Mashup Score: 0
A new cohort analysis suggest one-year intravitreal treatment burden can be significantly reduced when patients are only administered brolucizumab.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Brolucizumab Comparable to Aflibercept for DME - 3 year(s) ago
Data from the KITE study shows that ≥50% of brolucizumab patients maintained a 12-week interval schedule through 52 weeks.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
New from #ARVO2021 “#Brolucizumab 6mg showed superior improvements versus #aflibercept 2mg in the change from baseline in central subfield thickness over the period of Week 40 through Week 52." https://t.co/CsTZynjzsg
-
-
Mashup Score: 0Telehealth Could Be Feasible Alternative in Ophthalmology - 3 year(s) ago
Patients who utilized virtual and in-person visits had comparable numbers of follow-ups, referrals, and outpatient surgeries.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
“Results from the KITE study show that #brolucizumab offers the potential for robust vision gains and superior anatomical outcomes with q12w treatment intervals in more than 50% of patients with #DME." #ARVO2021 https://t.co/CZ2siysil2
-
-
Mashup Score: 3Brolucizumab Comparable to Aflibercept for DME - 3 year(s) ago
Data from the KITE study shows that ≥50% of brolucizumab patients maintained a 12-week interval schedule through 52 weeks.
Source: HCPLiveCategories: General Medicine News, Latest HeadlinesTweet-
New #ARVO2021 data compares #brolucizumab to #aflibercept in patients with #DME. https://t.co/CsTZynjzsg
-
-
Mashup Score: 0Retinal Physician - Beovu Meets Endpoints in Phase 3 DME Study - 3 year(s) ago
Article Novartis announced positive findings from the first interpretable results of the 571-patient phase 3 KESTREL study, assessing the efficacy and safety of Beovu (brolucizumab) 3 mg and 6 mg in diabetic macular edema (DME). The trial met its primary endpoint of noninferiority in change in…
Source: Retinal PhysicianCategories: Latest Headlines, OphthalmologyTweet-
Novartis announced positive findings from the first interpretable results of the 571-patient phase 3 KESTREL study, assessing the efficacy and safety of #brolucizumab 3 mg and 6 mg in #diabeticmacularedema. https://t.co/P0IZZuV2gY
-
-
Mashup Score: 0Retinal Physician - Retinal Physician Insider Podcast - 3 year(s) ago
Retinal Physician Insider Podcast Episode 3: Strategies for Choosing an anti-VEGF Treatment Sponsored by Novartis Peter Kaiser, MD, and Michael Singer, MD, discuss strategies for choosing an anti-VEGF treatment based on patients’ personal needs, how to handle non-responders, and what do to when inflammation is a…
Source: Retinal PhysicianCategories: Latest Headlines, OphthalmologyTweet-
Peter Kaiser, MD, and Timothy Murray, MD, MBA, discuss the HAWK and HARRIER phase 3 studies evaluating the safety and efficacy of #brolucizumab for wet AMD. https://t.co/TOXEFV4Ady https://t.co/2a2Omi69le
-
-
Mashup Score: 0Retinal Physician - Retinal Physician Insider Podcast - 3 year(s) ago
Retinal Physician Insider Podcast Episode 3: Strategies for Choosing an anti-VEGF Treatment Sponsored by Novartis Peter Kaiser, MD, and Michael Singer, MD, discuss strategies for choosing an anti-VEGF treatment based on patients’ personal needs, how to handle non-responders, and what do to when inflammation is a…
Source: Retinal PhysicianCategories: Latest Headlines, OphthalmologyTweet-
Peter Kaiser, MD, and Timothy Murray, MD, MBA, discuss the HAWK and HARRIER phase 3 studies evaluating the safety and efficacy of #brolucizumab for wet AMD. https://t.co/qqYbHVkJEK https://t.co/QZbnolsAPC
-
-
Mashup Score: 0Retinal Physician - Retinal Physician Insider Podcast - 3 year(s) ago
Chief Medical Editor Peter Kaiser, MD, will interview key retina surgeons regarding their clinical experience and honest conversations on managing patients during COVID, ensuring adherence to treatment regimens, how they talk to patients and handling durability during the pandemic. Episode 1: Age-related macular degeneration Sponsored by Novartis Peter Kaiser, MD, and Jeffrey Heier, MD, examine…
Source: Retinal PhysicianCategories: Latest Headlines, OphthalmologyTweet-
Introducing the Retinal Physician Insider podcast! Peter Kaiser, MD, and Jeffrey Heier, MD, examine the findings of the Novartis-appointed Safety Review Committee’s assessment of post-marketing cases of inflammation after the approval of #brolucizumab. https://t.co/qqYbHVkJEK https://t.co/XdfBot12jS
-
-
Mashup Score: 2Risk of inflammation, retinal vasculitis and retinal occlusion-related events with brolucizumab: post-hoc review of HAWK and HARRIER - 3 year(s) ago
An independent Safety Review Committee (SRC; supported by Novartis Pharma AG [Basel, Switzerland]) analyzed investigator-reported cases of intraocular inflammation (IOI), endophthalmitis and retinal arterial occlusion in the phase 3 HAWK and HARRIER trials of brolucizumab versus aflibercept in neovascular age-related macular degeneration (nAMD).
Source: OphthalmologyCategories: Latest Headlines, OphthalmologyTweet-
An independent Safety Review Committee analyzed investigator-reported cases of intraocular #inflammation following #brolucizumab treatment. They identified signs of retinal vasculitis with or without retinal vascular occlusion & assoc. risk of VA loss https://t.co/mbs1rhK2q4 https://t.co/uBbFG9crgA
-
-
Mashup Score: 0Retinal Physician - October 2020 - 4 year(s) ago
Advertisement This month I have the pleasure of interviewing Professor Richard Gale, consultant and medical ophthalmologist and Professor at the University…
Source: Retinal PhysicianCategories: Latest Headlines, OphthalmologyTweet-
In this issue of the Retina Minute newsletter, Dr. Singer and Richard Gale discuss "Group Team Treat" a think tank regarding inflammation with #brolucizumab: https://t.co/Aa9KYbgYZX https://t.co/c1OETbipav
-
In new data presented at #ARVO22, a team of Cleveland-based investigators observed similar clinical outcomes yet more treatment burden among patients on an alternating #antiVEGF regimen compared to patients administered only #brolucizumab for 12 months. https://t.co/zYDmwnpwt1